| Schedule of Financial Income, Net |
| | | Nine months ended | | | Three months ended | | | | | September 30, 2026 | | | September 30, 2025 | | | September 30, 2026 | | | September 30, 2025 | | | Revaluation of investments: | | | | | | | | | | | | | | Revaluation of Scilex, net (see note 4) | | | (3,428 | ) | | | 38,457 | | | | (5,895 | ) | | | 34,163 | | | Revaluation of Hapisga, net (see note 7) | | | 9,441 | | | | 853 | | | | (537 | ) | | | 418 | | | Revaluation of Alpha Tau, net (see note 8) | | | 174,500 | | | | 29,691 | | | | 41,083 | | | | 22,306 | | | Revaluation of RoyaltyVest loan, net (see note 6) | | | (549 | ) | | | 294 | | | | (444 | ) | | | 1,324 | | | Revaluation of Profit Sharing Loan Agreement (see note 4) | | | 193 | | | | 161 | | | | 196 | | | | 64 | | | Revaluation of Ruby Capital (see note 4) | | | (50 | ) | | | - | | | | (15 | ) | | | - | | | Revaluation of Lifeward (see note 8) (1) | | | 1,140 | | | | - | | | | (3,927 | ) | | | - | | | Revaluation of 83 Wythe Loan and Warren at Bay Loan (see note 4) | | | (424 | ) | | | - | | | | (64 | ) | | | - | | | Revaluation of Marketable Securities (see note 3) | | | (1,911 | ) | | | 2,786 | | | | 147 | | | | 2,686 | | | | | $ | 178,912 | | | $ | 72,242 | | | $ | 30,544 | | | $ | 60,961 | | | Loan extension fee income – Scilex (see note 4) | | | 1,000 | | | | - | | | | 1,000 | | | | - | | | Interest Income | | | 524 | | | | 2,135 | | | | 150 | | | | 510 | | | Exchange rate | | | (127 | ) | | | 106 | | | | (81 | ) | | | (8 | ) | | Other | | | 180 | | | | (205 | ) | | | 284 | | | | 7 | | | | | | 180,489 | | | | 74,278 | | | | 31,897 | | | | 61,470 | | | (1) | For the nine months ended September 30, 2026, includes revaluation gains of $88 on the Lifeward shares and $3,655 on the Lifeward warrants, offset by a revaluation loss of $1,144 on the Initial Note and a loss of $1,459 recognized upon the conversion of the Secured Promissory Note and the additional note into the Initial Note. |
|